Medclair (MCLR) Q3 2025 earnings summary

Executive summary

• Achieved robust growth and profitability in Q3 2025, with continued execution of long-term strategy and expansion into new markets.

• Focused on sustainable nitrous oxide management, reducing CO₂ emissions equivalent to 464,000 tons, or emissions from 108,200 gasoline cars annually.

Financial highlights

• Q3 2025 order intake was 14.9 MSEK (11.2), net sales 10.5 MSEK (3.5), EBITDA 1.8 MSEK (-1.4), net income 0.3 MSEK (-2.8), EPS 0.00 SEK (-0.04), all compared to Q3 2024.

• For Jan–Sep 2025, order intake reached 49.6 MSEK (40.3), net sales 42.0 MSEK (27.8), EBITDA 11.8 MSEK (0.0), net income 6.8 MSEK (1.0), EPS 0.08 SEK (0.01), all year-over-year.

• Cash flow from operations for Jan–Sep 2025 was 1.6 MSEK (-0.7), with cash and equivalents at 1.8 MSEK (1.9) at period end.

• Equity at period end was 55.9 MSEK (53.5), with a solid equity ratio of 87% (84%).

Outlook and guidance

• Addressable market estimated at SEK 17 billion, with SEK 3 billion commercially available.

• Strong demand driven by regulatory and sustainability trends in healthcare, dental, recycling, and manufacturing sectors.

• Continued focus on innovation, controlled growth, and profitability to support long-term expansion.